1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol [Internet] 1984 Sep [cited 2014 Mar 26];132(3):474–479; available from: http://www.ncbi.nlm.nih.gov/pubmed/6206240
2. Handzel DM, Briesen S, Rausch S, Kälble T. Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complications. Dtsch Arztebl Int [Internet] 2012 May [cited 2012 Jul 18];109(21):379–384; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3371631&tool=pmcentrez&rendertype=abstract
3. Steers WD. 5alpha-reductase activity in the prostate. Urology [Internet] 2001 Dec [cited 2014 Mar 26];58(6 Suppl 1):17–24; discussion 24; available from: http://www.ncbi.nlm.nih.gov/pubmed/11750244
4. Gravas S, Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Uroweb 2014; available at: http://www.uroweb.org/guidelines/online-guidelines/?no_cache=1 , accessed May 20, 2014
5. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med [Internet] 1995 Jan 12 [cited 2014 Mar 26];332(2):75–79; available from: http://www.ncbi.nlm.nih.gov/pubmed/7527493